Literature DB >> 12841380

Importance of CD4+ helper T-cells in antitumor immunity.

Hiroshi Shiku1.   

Abstract

CD8+ cytotoxic T-lymphocytes are major effector cells involved in immunologically specific tumor destruction in vivo, and CD4+ T-cells are essential for controlling this CD8+ T-cell-dependent tumor eradication. The presence of CD4+ T-cells with distinct functional roles has been recognized. The further understanding of the complexity of antitumor immune responses by CD4+ T-cells may be crucial for designing more effective cancer vaccines.

Entities:  

Mesh：

Year:  2003        PMID： 12841380     DOI： 10.1007/bf02986610

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  22 in total

1.  Cutting edge: precursor frequency affects the helper dependence of cytotoxic T cells.

Authors:  Justine D Mintern; Gayle M Davey; Gabrielle T Belz; Francis R Carbone; William R Heath
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

Review 2.  Crossregulation between Th1 and Th2 cells.

Authors:  P A Morel; T B Oriss
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

3.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

Review 4.  CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

Authors:  P A Cohen; L Peng; G E Plautz; J A Kim; D E Weng; S Shu
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

5.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

6.  Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.

Authors:  F Fallarino; U Grohmann; R Bianchi; Carmine Vacca; M C Fioretti; P Puccetti
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

7.  Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity.

Authors:  N Casares; J J Lasarte; A L de Cerio; P Sarobe; M Ruiz; I Melero; J Prieto; F Borrás-Cuesta
Journal:  Eur J Immunol       Date:  2001-06       Impact factor: 5.532

8.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

Review 9.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

10.  CD4 T cells and their role in antitumor immune responses.

Authors:  R E Toes; F Ossendorp; R Offringa; C J Melief
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307
View more
  11 in total

1.  Preoperative sorting of circulating T lymphocytes in patients with esophageal squamous cell carcinoma: its prognostic significance.

Authors:  Tadahiro Nozoe; Yoshihiko Maehara; Keizo Sugimachi
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

2.  Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma.

Authors:  Yang Ling; Lieying Fan; Chunlei Dong; Jing Zhu; Yongping Liu; Yan Ni; Changtai Zhu; Changsong Zhang
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

3.  Camphor white oil induces tumor regression through cytotoxic T cell-dependent mechanisms.

Authors:  Yalda Moayedi; Sophie A Greenberg; Blair A Jenkins; Kara L Marshall; Lina V Dimitrov; Aislyn M Nelson; David M Owens; Ellen A Lumpkin
Journal:  Mol Carcinog       Date:  2019-01-20       Impact factor: 4.784

4.  A polysaccharide component from Strongylocentrotus nudus eggs inhibited hepatocellular carcinoma in mice by activating T lymphocytes.

Authors:  Min Zhang; Yang Liu; Jingwen Li; Mengyun Ke; Jie Yu; Jie Dou; Hui Wang; Changlin Zhou
Journal:  Oncol Lett       Date:  2017-01-19       Impact factor: 2.967

5.  Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo.

Authors:  Qiang Zhou; Xiaocai Yan; Jill Gershan; Rimas J Orentas; Bryon D Johnson
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

6.  The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells.

Authors:  Andrea Balogh; Eszter Persa; Enikő Noémi Bogdándi; Anett Benedek; Hargita Hegyesi; Géza Sáfrány; Katalin Lumniczky
Journal:  Inflamm Res       Date:  2012-10-19       Impact factor: 4.575

Review 7.  STAT3 activation: A key factor in tumor immunoescape.

Authors:  Cédric Rébé; Frédérique Végran; Hélène Berger; François Ghiringhelli
Journal:  JAKSTAT       Date:  2013-01-01

Review 8.  STAT3, a Master Regulator of Anti-Tumor Immune Response.

Authors:  Cédric Rébé; François Ghiringhelli
Journal:  Cancers (Basel)       Date:  2019-08-30       Impact factor: 6.639

9.  The resveratrol analogue, HS‑1793, enhances the effects of radiation therapy through the induction of anti‑tumor immunity in mammary tumor growth.

Authors:  Joong Sun Kim; Soo Kyung Jeong; Su Jung Oh; Chang Geun Lee; Yeong Rok Kang; Wol Soon Jo; Min Ho Jeong
Journal:  Int J Oncol       Date:  2020-03-19       Impact factor: 5.650

Review 10.  Platinum Derivatives Effects on Anticancer Immune Response.

Authors:  Cédric Rébé; Lucie Demontoux; Thomas Pilot; François Ghiringhelli
Journal:  Biomolecules       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.